Mermade 12 Synthesizer
The MerMade 12 Oligonucleotide synthesizer is designed to synthesize DNA, RNA and LNA oligonucleotides in a column format using standard or modified chemistries.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The MerMade 12 Oligonucleotide synthesizer is designed to synthesize DNA, RNA and LNA oligonucleotides in a column format using standard or modified chemistries. The Mermade 12 is ideal for a lab requiring medium throughput with maximum flexibility. This instrument has been placed in many universities, pharma and diagnostic companies operating in cGMP environments. The machine is available in a 12-column configuration with up to 24 amidite positions. It is capable of making a combination of standard, degenerate, and modified oligos in the same run with scales varying from 50nmole to 200umole (over 400umole with certain supports). Synthesis time depends on chemistry and desired product quality but a typical run time is less than 2 hours for 12 columns of DNA 20mers. No other machine offers the flexibility, upgrade ability, dependability, efficiency and ease of use than the MM 12 at any cost. Please contact our Sales department for pricing.
Simplifying the journey from molecular diagnostic assay development to commercialization
Molecular diagnostics (MDx) is rapidly advancing, with a growing array of DNA- and RNA-based tests now available to physicians, pharmacists, geneticists, research scientists, and other healthcare professionals.
As labs work with human and microbial genes, test developers must comply with clinical guidelines and regulations. Both established companies and start-ups face challenges, including meeting regulatory standards, ensuring quality, and managing supply chain issues. Early planning and robust partnerships are key to overcoming these obstacles.
This essential guide explores these challenges through detailed case studies. It covers everything from early development and assay formulation, to supply chain security, offering expert insights on successfully bringing PCR, next-generation sequencing (NGS), and other nucleic acid-based diagnostic tests to market.
